Clinical Trials and Meta-Analysis

Evidence-Based Cardiology: Third Edition

Volumn , Issue , 2010, Pages 26-37

  Emberson, Jonathan R ^a   Baigent, Colin ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Availability of large scale randomized trials; Biases affecting reliability of meta analysis; Clinical trials and meta analysis; Clinical trials minimizing biases and random errors; Homogeneity serious defect in clinical trial design; Trial design facilitation limiting amount of information recorded

Indexed keywords

EID: 84887172120     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444309768.ch3     Document Type: Chapter

References (79)

1. Fibrinolytic Therapy Trialists'(FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. L ancet 1994; 343: 311-22.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
3. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
4. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336: 847-60.
5. Antithrombotic Trialists'Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. B MJ 2002; 324: 71-86.
6. Blood Pressure Lowering Treatment Trialists'Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
8. Cholesterol Treatment Trialists Collaboration. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
9. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
10. MERIT-HF. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
11. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001; 357: 373-80.
12. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455-62.
13. Collins R, Peto R, Gray R, Parish S. Large scale randomized evidence: trials and overviews. In: Weatherall D, Ledingham JGG, Warrell DA, eds. Oxford Textbook of Medicine, Vol. 1. Oxford: Oxford University Press, 1996.
14. Armitage P. The role of randomization in clinical trials. S tat Med 1982; 1: 345-52.
15. Kunz R, Oxman AD. The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. BMJ 1998; 317: 1185-90.
16. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-16.
17. Peto R. Failure of randomisation by " sealed " envelope. Lancet 1999; 354: 73.
18. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press 1992; 1: 113-19.
19. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
20. Pedersen TR, Faergeman O, Kastelein JJ et al. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study. Am J Cardiol 2004; 94: 720-4.
21. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980; 303: 1038-41.
22. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
23. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997; 16: 1017-29.
24. Antiplatelet Trialists'Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
25. Peto R. Statistical aspects of cancer trials, In: Halnan KE, ed. Treatment of Cancer. London: Chapman and Hall, 1982.
26. Efron BMC. Stein's paradox in statistics. Sci Am 1977; 236: 119-27.
27. Collins R, Julian D. British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction. Br Heart J 1991; 66: 250-5.
28. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
29. Doyal L. Informed consent in medical research. Journals should not publish research to which patients have not given fully informed consent-with three exceptions. BMJ 1997; 314: 1107-11.
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
31. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003; 289: 2545-53.
32. Collins R, Doll R, Peto R. Ethics of clinical trials. In: Williams CJ, ed. Introducing New Treatments for Cancer: Practical, Ethical and Legal Problems. Chichester: John Wiley, 1992.
33. Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med 1988; 7: 1231-42.
34. Armitage P, McPherson CK, Rowe BC. Repeated significance tests on accumulating data. J R Stat Soc (Series A) 1969; 132: 235-44.
35. Demets DL. Practical aspects in data monitoring: a brief review. Stat Med 1987; 6: 753-60.
36. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials 1984; 5: 348-61.
37. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971; 44: 793-7.
38. Schulz KF, Chalmers I, Altman DG, Grimes DA, Dore CJ. The methodologic quality of randomization as assessed from reports of trials in specialist and general medical journals. Online J Curr Clin Trials 1995; Doc No 197.
39. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
40. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology . BMJ 1996; 312: 742-4.
41. Dickersin K, Min YI. Publication bias: the problem that won't go away. Ann NY Acad Sci 1993; 703: 135-46; discussion 146-8.
42. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992; 267: 374-8.
43. Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. Publication bias and clinical trials. Control Clin Trials 1987; 8: 343-53.
44. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867-72.
45. Counsell CE, Clarke MJ, Slattery J, Sandercock PA. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis? BMJ 1994; 309: 1677-81.
46. Egger M, Smith GD. Misleading meta-analysis. BMJ 1995; 310: 752-4.
47. Morton BC, Nair RC, Smith FM, McKibbon TG, Poznanski WJ. Magnesium therapy in acute myocardial infarction-a double-blind study. Magnesium 1984; 3: 346-52.
48. Rasmussen HS, McNair P, Norregard P, Backer V, Lindeneg O, Balslev S. Intravenous magnesium in acute myocardial infarction . Lancet 1986; 1: 234-6.
49. Smith LF, Heagerty AM, Bing RF, Barnett DB. Intravenous infusion of magnesium sulphate after acute myocardial infarction: effects on arrhythmias and mortality. Int J Cardiol 1986; 12: 175-83.
50. Abraham AS, Rosenmann D, Kramer M et al. Magnesium in the prevention of lethal arrhythmias in acute myocardial infarction. Arch Intern Med 1987; 147: 753-5.
51. Feldstedt M, Boesgaard S, Bouchelouche P et al. Magnesium substitution in acute ischaemic heart syndromes. Eur Heart J 1991; 12: 1215-18.
52. Shechter M, Hod H, Marks N, Behar S, Kaplinsky E, Rabinowitz B. Beneficial effect of magnesium sulfate in acute myocardial infarction. Am J Cardiol 1990; 66: 271-4.
53. Ceremuzynski L, Jurgiel R, Kulakowski P, Gebalska J. Threatening arrhythmias in acute myocardial infarction are prevented by intravenous magnesium sulfate. Am Heart J 1989; 118: 1333-4.
54. Bertschat F. Antiarrhythmic effects of magnesium infusions in patients with acute myocardial infarction. Magnesium Bull 1989; 11: 155-8.
55. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992; 339: 1553-8.
56. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
57. Shechter M, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B. Magnesium therapy in acute myocardial infarction when patients are not candidates for thrombolytic therapy. Am J Cardiol 1995; 75: 321-3.
58. Thogersen A, Johnson O, Wester P. Effects of magnesium infusion on thrombolytic and non-thrombolytic treated patients with acute myocardial infarction. Int J Cardiol 1993; 39: 13-22.
59. Raghu C, Peddeswata P, Seshagiri D. Protective effect of intravenous magnesium in acute myocardial infarction following thrombolytic therapy. Int J Cardiol 1999; 71: 209-15.
60. Gyamlani G, Kulkarni A. Benefits of magnesium in acute myocardial infarction: timing is crucial. Am Heart J 2000; 139: 703.
61. Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360: 1189-96.
62. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-29.
63. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
64. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress Cardiovasc Dis 1985; 27: 335-371.
65. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351-5.
66. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999; 18: 2693-708.
67. Greenland S, Morgenstern H. Ecological bias, confounding, and effect modification. Int J Epidemiol 1989; 18: 269-74.
68. Chalmers I. The Cochrane Collaboration: preparing, maintaining, and disseminating systematic reviews of the effects of health care. Ann NY Acad Sci 1993; 703: 156-63; discussion 163-5.
69. Early Breast Cancer Trialists'Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71-85.
70. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 1-15.
71. Cholesterol Treatment Trialists'(CTT) Collaboration. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol 1995; 75: 1130-4.
72. Deeks JJ, Dinnes J, D'Amico R et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7: iii-x, 1-173.
73. Sheldon TA. Please bypass the PORT. BMJ 1994; 309: 142-3.
74. Peto R. Clinical trial methodology. Biomedicine 1978; 28: 24-36.
75. Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis-a new controversy regarding an old drug. The pitfalls of inappropriate methods. C irculation 1986; 73: 14-18.
76. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
77. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215-18.
78. Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-90.
79. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.